Dual 5-Alpha Reductase Inhibitor for Androgenetic Alopecia (AGA)
Androgenetic alopecia is primarily driven by dihydrotestosterone (DHT), which shortens the anagen phase and leads to progressive follicular miniaturization. Dutasteride inhibits both Type I and Type II 5-alpha reductase enzymes, resulting in a significant reduction in scalp DHT levels and improved follicular preservation. Liposomal delivery enhances follicular targeting while minimizing systemic exposure.
Key Benefits
· Most comfortable Injectable Dutasteride DUTASTERIDE 0.01% IN LIPOSOMES
· Effectively reduces scalp DHT levels
· Slows progression of follicular miniaturization
· Promotes thicker, stronger hair regrowth
· Demonstrates superior efficacy compared to finasteride
· Long half-life ensures sustained therapeutic effect
· Well tolerated in mesotherapy with reduced systemic side effects